WO2018189020A3 - Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals - Google Patents

Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals Download PDF

Info

Publication number
WO2018189020A3
WO2018189020A3 PCT/EP2018/058701 EP2018058701W WO2018189020A3 WO 2018189020 A3 WO2018189020 A3 WO 2018189020A3 EP 2018058701 W EP2018058701 W EP 2018058701W WO 2018189020 A3 WO2018189020 A3 WO 2018189020A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
vitamin
levels
homocystein
individuals
Prior art date
Application number
PCT/EP2018/058701
Other languages
French (fr)
Other versions
WO2018189020A2 (en
Inventor
Gene BOWMAN
Julie HUDRY-LABBE
Jeroen Antonius Johannes Schmitt
Corina BOSCHAT
Claus Rieker
Original Assignee
Nestec S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/074731 external-priority patent/WO2018060396A1/en
Priority claimed from EP17193916.8A external-priority patent/EP3388061A1/en
Priority to JP2019551444A priority Critical patent/JP7270547B2/en
Priority to EP18714287.2A priority patent/EP3609491A2/en
Priority to CA3054864A priority patent/CA3054864A1/en
Priority to AU2018251092A priority patent/AU2018251092B2/en
Priority to CN201880018724.5A priority patent/CN110430873A/en
Priority to US16/603,688 priority patent/US20210263048A1/en
Application filed by Nestec S.A. filed Critical Nestec S.A.
Priority to BR112019020008A priority patent/BR112019020008A2/en
Priority to MX2019010828A priority patent/MX2019010828A/en
Publication of WO2018189020A2 publication Critical patent/WO2018189020A2/en
Publication of WO2018189020A3 publication Critical patent/WO2018189020A3/en
Priority to JP2022129345A priority patent/JP7434459B2/en
Priority to US18/120,189 priority patent/US20230226097A1/en
Priority to AU2024200882A priority patent/AU2024200882A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.
PCT/EP2018/058701 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability WO2018189020A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR112019020008A BR112019020008A2 (en) 2017-04-11 2018-04-05 methods to identify predisposition to cognitive decline and agents to mitigate or prevent cognitive decline or improve cognitive ability
MX2019010828A MX2019010828A (en) 2017-04-11 2018-04-05 Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals.
EP18714287.2A EP3609491A2 (en) 2017-04-11 2018-04-05 Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals
CA3054864A CA3054864A1 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
AU2018251092A AU2018251092B2 (en) 2017-04-11 2018-04-05 Omega-3 fatty acid, homocystein and vitamin D levels to identify and attenuate cognitive aging in individuals
CN201880018724.5A CN110430873A (en) 2017-04-11 2018-04-05 Omega-3 fatty acid, homocysteine and the vitamin D level of cognition aging are identified and weakened in individual
US16/603,688 US20210263048A1 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
JP2019551444A JP7270547B2 (en) 2017-04-11 2018-04-05 Levels of omega-3 fatty acids, homocysteine and vitamin D to identify and reduce cognitive aging in individuals.
JP2022129345A JP7434459B2 (en) 2017-04-11 2022-08-15 Levels of omega-3 fatty acids, homocysteine and vitamin D to identify and reduce cognitive aging in individuals
US18/120,189 US20230226097A1 (en) 2017-04-11 2023-03-10 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
AU2024200882A AU2024200882A1 (en) 2017-04-11 2024-02-12 Omega-3 fatty acid, homocystein and vitamin D levels to identify and attenuate cognitive aging in individuals

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201762484119P 2017-04-11 2017-04-11
US201762484156P 2017-04-11 2017-04-11
US62/484,119 2017-04-11
US62/484,156 2017-04-11
PCT/EP2017/074731 WO2018060396A1 (en) 2016-09-29 2017-09-29 Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
EP17193916.8A EP3388061A1 (en) 2017-04-11 2017-09-29 Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
EP17193916.8 2017-09-29
EPPCT/EP2017/074731 2017-09-29
US201762580574P 2017-11-02 2017-11-02
US62/580,574 2017-11-02
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
EPPCT/EP2017/082148 2017-12-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/603,688 A-371-Of-International US20210263048A1 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability
US18/120,189 Division US20230226097A1 (en) 2017-04-11 2023-03-10 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability

Publications (2)

Publication Number Publication Date
WO2018189020A2 WO2018189020A2 (en) 2018-10-18
WO2018189020A3 true WO2018189020A3 (en) 2019-04-18

Family

ID=63792325

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
PCT/EP2018/058710 WO2018189022A1 (en) 2017-04-11 2018-04-05 Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
PCT/EP2018/058701 WO2018189020A2 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
PCT/EP2018/058710 WO2018189022A1 (en) 2017-04-11 2018-04-05 Compositions and methods that attenuate cognitive aging in individuals who do not have dementia

Country Status (2)

Country Link
US (1) US20230226097A1 (en)
WO (3) WO2018188771A1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003074A1 (en) * 2000-07-04 2002-01-10 Axis-Shield Asa Diagnostic method for alzheimer's disease based on holo-transcobalamin ii
US20020182196A1 (en) * 2001-04-19 2002-12-05 Mccleary Edward Larry Composition and method for normalizing impaired or deteriorating neurological function
WO2010143053A1 (en) * 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2014122290A1 (en) * 2013-02-08 2014-08-14 Centre National De La Recherche Scientifique (Cnrs) Dyrk1a marker for alzheimer's disease
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
US20150086625A1 (en) * 2008-12-31 2015-03-26 Nitromega Corp. Nutraceuticals containing nitro fatty acids
WO2015140545A1 (en) * 2014-03-20 2015-09-24 Isis Innovation Limited Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species
WO2016207794A1 (en) * 2015-06-22 2016-12-29 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003074A1 (en) * 2000-07-04 2002-01-10 Axis-Shield Asa Diagnostic method for alzheimer's disease based on holo-transcobalamin ii
US20020182196A1 (en) * 2001-04-19 2002-12-05 Mccleary Edward Larry Composition and method for normalizing impaired or deteriorating neurological function
US20150086625A1 (en) * 2008-12-31 2015-03-26 Nitromega Corp. Nutraceuticals containing nitro fatty acids
WO2010143053A1 (en) * 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
WO2011143587A1 (en) * 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2014122290A1 (en) * 2013-02-08 2014-08-14 Centre National De La Recherche Scientifique (Cnrs) Dyrk1a marker for alzheimer's disease
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2015140545A1 (en) * 2014-03-20 2015-09-24 Isis Innovation Limited Combination therapy comprising an omega-3 fatty acid, a folate species and a vitamin b12 species
WO2016207794A1 (en) * 2015-06-22 2016-12-29 Nestec Sa Compositions and methods for enhancing neurogenesis in animals
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBERGER-GATEAU P: "Nutrition and brain aging: How can we move ahead?", EUROPEAN JOURNAL OF CLINICAL NUTRITION, NATURE PUBLISHING GROUP, GB, vol. 68, no. 11, 13 November 2014 (2014-11-13), pages 1245 - 1249, XP009503472, ISSN: 0954-3007, DOI: 10.1038/EJCN.2014.177 *
BOWMAN GENE ET AL: "Nutrient biomarker patterns and cognitive decline in older adults", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 28, no. 1, Suppl. S, 31 March 2014 (2014-03-31), pages 124.6, XP009503473, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
WO2018188771A1 (en) 2018-10-18
WO2018189020A2 (en) 2018-10-18
US20230226097A1 (en) 2023-07-20
WO2018189022A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
EA201892489A1 (en) NUMBER OF TARGETS FOR MULTIPLEX OPTIMIZED AMPLIFICATION WITH NON-CONFORMITY (MOMA)
AU2017367238A8 (en) Methods and systems for characterizing analytes using nanopores
EA201792389A1 (en) REAL-TIME PCR FOR MULTIPLEX OPTIMIZED AMPLIFICATION WITH NON-CORRESPONDENCE (MOMA) AND FOR ASSESSMENT OF NUCLEAR DNA
MX2016004865A (en) Social relationship analysis method and device.
BR112017019774A2 (en) use of a porous capillary membrane to determine the amount of rolling circle amplification products
CL2014002975A1 (en) In vitro method for the diagnosis and surveillance of cancer, which comprises determining the ratio between treg cells and another group of t cells, selected from th17, th1 and / or th2.
CL2018002548A1 (en) Regulation of ornithine metabolism to increase the content of mannose-rich glycoforms of recombinant proteins. (Divisional application 201601786)
MX2019010828A (en) Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals.
EA201791766A1 (en) COMPOSITIONS OF MILLIKAPSULES CONTAINING POLYINSATURATED FREE FATTY ACIDS
BR112016006383A8 (en) methods for extracting a soluble protein, producing a composition, and producing a solid or semi-solid support
MX2017009752A (en) Host dna as a biomarker of crohn's disease.
WO2016196993A3 (en) Multi-mediator reagent formulations for use in electrochemical detection
WO2018128706A3 (en) Modified nucleic acids for nanopore analysis
MX2016007148A (en) A-glucan assay methods.
WO2018189020A3 (en) Omega-3 fatty acid, homocystein and vitamin d levels to identify and attenuate cognitive aging in individuals
MX2015007494A (en) Method for the diagnosis of metachromatic leukodystrophy.
WO2017009719A3 (en) Nucleic acid detection kit and nucleic acid detection method, which use nanoparticles
MX2020001818A (en) Image capillary isoelectric focusing to analyze protein variants in a sample matrix.
PH12018502207A1 (en) Methods of manufacturing nutritional formulations
WO2016149386A8 (en) Biomarkers for malaria diagnosis
MY178495A (en) Shuffle play method and device
WO2015200692A3 (en) Methods and compositions for selective detection of homocysteine
PL410179A1 (en) Method for obtaining erythritol
GB2553736A (en) Method for identification of a deficient BRCA1 function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18714287

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3054864

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018251092

Country of ref document: AU

Date of ref document: 20180405

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019551444

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019020008

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018714287

Country of ref document: EP

Effective date: 20191111

ENP Entry into the national phase

Ref document number: 112019020008

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190925